Peptide Therapy
Safety profiles, monitoring requirements, and risk assessment across peptide compounds.
FDA warnings now cover 33+ weight-loss supplements adulterated with toxic yellow oleander. Here is what patients and physicians need to know to stay safe.
A clinical guide to senolytics contraindications: active cancer, cardiac risk, drug interactions, active infection, and the 2026 demyelination finding from PNAS.
Melanotan 2 (MT-II) tans skin and triggers erections via melanocortin receptors. Two tiny trials, many case reports of nevi, melanoma and priapism.
PNC-27 is a p53-derived peptide studied in cell lines and mice. No human trial has been published or registered. What was tested, what is unknown.
Methylene blue is a potent MAOI that can trigger life-threatening serotonin syndrome. Learn which medications are dangerous to combine and clinical safety protocols.
A clinical guide to BPC-157 contraindications, relative cautions, and drug interactions — covering cancer patients, transplant recipients, pregnancy, and autoimmune conditions.
Berberine inhibits CYP3A4 and P-gp, creating clinically significant interactions with statins, warfarin, cyclosporine, and more. A physician's evidence-based guide.
Ashwagandha is generally well-tolerated, but specific groups face real risks. A physician reviews thyroid effects, autoimmune concerns, drug interactions, and who to avoid it.
Evidence-based guide to metformin dosing in CKD patients. eGFR cutoffs, lactic acidosis risk, FDA label changes, and how longevity physicians adjust protocol for renal impairment.
Which therapeutic peptides are banned under WADA's anti-doping code in 2026, which are permitted, and how athletes can navigate therapeutic use exemptions.
A physician's guide to NAD+ IV therapy contraindications — cancer history, active infections, G6PD deficiency, cardiac conditions, and pregnancy.
A physician's guide to chelation therapy safety — covering EDTA, DMPS, and DMSA risks, contraindications, mineral depletion, and clinical monitoring protocols.
A clinical breakdown of ozone therapy risks by administration route, contraindications, and how to evaluate whether ozone treatment is appropriate for you.
A physician's guide to NAD+ IV therapy side effects: what causes them, which are common vs serious, how to minimize discomfort, and who should avoid treatment.
Honest physician's answer about FDA approval for peptide therapy. Which peptides are approved, which are investigational, off-label use, and the European regulatory landscape.
Complete guide to chelation therapy side effects. Common reactions, serious risks, mineral depletion, monitoring requirements, and how to minimize adverse effects.
What to expect during and after PEMF therapy — common responses, contraindications, how to titrate sessions, and when temporary symptom increases are normal.
Pentosan polysulfate maculopathy explained by Dr. med. univ. Julian Douwes. Retinal toxicity risk, screening guidelines, reversibility questions, and what every PPS user must know.
Honest assessment of BPC-157 side effects, safety data, FDA warnings, and theoretical risks. What we know, what we don't, and what to watch for.
Evidence-based BPC-157 dosing protocols. Subcutaneous vs oral routes, loading vs maintenance, body weight calculations, and clinical observations.
Honest assessment of TB-500 side effects, WADA ban context, theoretical risks, and what clinical experience shows about Thymosin Beta-4 safety.
Step-by-step guide to subcutaneous peptide injection. Equipment, reconstitution, injection sites, rotation, storage, and sterility from a physician's perspective.
Dihexa safety analysis by Dr. med. univ. Julian Douwes. The HGF/c-Met oncogenic pathway concern, retracted research, failed clinical trials, and what patients must understand.
Comprehensive guide to peptide therapy safety. Regulatory status, quality concerns, side effects, contraindications, and why physician oversight matters.
